Literature DB >> 1851134

Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity.

C M Lawson1, H L O'Donoghue, H E Farrell, G R Shellam, W D Reed.   

Abstract

Certain murine monoclonal antibodies (mAb) raised against structural proteins of mouse cytomegalovirus (MCMV) display distinct patterns of multiple organ-autoreactivity in addition to their viral specificities. We analysed the autoreactivity of five such mAb by immunoperoxidase histochemistry, western immunoblot and enzyme-linked immunosorbent assay (ELISA). Four mAb recognized cellular autoantigens in the salivary gland, lung, heart, liver, kidney, ileum, striated muscle and brain, as detected by immunoperoxidase histochemistry. However, the mAb showed different specificities for nuclear, cytoplasmic and surface membrane antigens on various cell types in addition to common autoreactivities. Immunoblot analyses showed that some of the mAb recognized polypeptides of various molecular weights obtained from 100,000 g supernatants of normal BALB/c liver, brain, striated and cardiac muscle homogenates. Reactivity of the mAb with a 200,000 molecular weight (MW) polypeptide was similar to our previous finding of the reaction of late immune polyclonal sera with a 200,000 MW polypeptide, the heavy chain of myosin. The mAb reacted to the cardiac isoform of myosin as determined by ELISA and immunoblot. Reactivity of mAb with cardiac myosin, as detected by immunoblot, was removed by absorption with cardiac myosin and recovered in the eluate. However, cardiac myosin used in a competitive inhibition ELISA did not abrogate the reactivity of the mAb with MCMV antigens. These anti-MCMV mAb appear to be multispecific for both virus and self-antigens, including cardiac myosin, and possibly recognize these different antigens through partly similar or distinct antigen-binding sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851134      PMCID: PMC1384406     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Protective effect of early serum from mice after cytomegalovirus infection.

Authors:  T P Araullo-Cruz; M Ho; J A Armstrong
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

2.  Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens.

Authors:  S Beck; B G Barrell
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

3.  Smooth-muscle antibodies and other tissue antibodies in cytomegalovirus infection.

Authors:  P Andersen; H K Andersen
Journal:  Clin Exp Immunol       Date:  1975-10       Impact factor: 4.330

4.  2.2-kilobase class of early transcripts encoded by cell-related sequences in human cytomegalovirus strain AD169.

Authors:  S I Staprans; D H Spector
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

5.  Monoclonal antibody to coxsackievirus B4 reacts with myocardium.

Authors:  J Saegusa; B S Prabhakar; K Essani; P R McClintock; Y Fukuda; V J Ferrans; A L Notkins
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

6.  Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression.

Authors:  R S Fujinami; J A Nelson; L Walker; M B Oldstone
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

7.  Mixed cryoimmunoglobulinaemia in infectious mononucleois and Cytomegalovirus mononucleosis.

Authors:  O Wager; J A Räsänen; A Hagman; E Klemola
Journal:  Int Arch Allergy Appl Immunol       Date:  1968

8.  A human cytomegalovirus-neutralizing monoclonal antibody recognizes a normal cell protein.

Authors:  S Michelson; M Tardy-Panit; R Colimon; M P Landini
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

9.  Multiple autoantibodies following cytomegalovirus infection: virus distribution and specificity of autoantibodies.

Authors:  W N Bartholomaeus; H O'Donoghue; D Foti; C M Lawson; G R Shellam; W D Reed
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

10.  Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice.

Authors:  C M Lawson; J E Grundy; G R Shellam
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

View more
  7 in total

1.  Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays.

Authors:  H Zhu; J P Cong; G Mamtora; T Gingeras; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 2.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

4.  Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin.

Authors:  D Fairweather; C M Lawson; A J Chapman; C M Brown; T W Booth; J M Papadimitriou; G R Shellam
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

5.  A murine cytomegalovirus-neutralizing monoclonal antibody exhibits autoreactivity and induces tissue damage in vivo.

Authors:  A J Chapman; H E Farrell; J A Thomas; J M Papadimitriou; M J Garlepp; A A Scalzo; G R Shellam
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

6.  Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis.

Authors:  C M Lawson; H L O'Donoghue; W D Reed
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

7.  B-cell activation following murine cytomegalovirus infection: implications for autoimmunity.

Authors:  P Price; S D Olver; A E Gibbons; G R Shellam
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.